Topotarget’s candidate drug belinostat has achieved Orphan Drug-status in the EU for the treatment of the indication Peripheral T-Cell Lymphoma (PTCL).
“Gaining Orphan Drug-status for belinostat for the treatment of PTCL in the European Union is an important milestone in our efforts to submit a registration application in this region. This is great news for Topotarget and potentially to patients with the rare disease PTCL, who are in need of new treatment options,” says CEO Anders Fink Vadsholt in a stock market release.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app